Congratulations to Thu Tran from the Lymphoma team, who was published as a co-author in an article recently published in the NEJM about Dr. Advani’s anti CD-47 study! This article was mentioned last week in the blog and can be read here. Great job, Thu!
CCTO staff: the Stanford Cancer Institute would love to hear about your clinical trial experiences.
Have you been touched by a Stanford cancer clinical trial? Your story will provide courage and hope to others. Let us know what motivates you in your work by submitting your story here.
- Have you been inspired by a patient or by a clinical trial?
- What drives you to work in cancer clinical research?
Ranjana Advani, MD, recently published findings from the anti-CD47 lymphoma study at Stanford. This phase 1 trial tested Hu5F9-G4 in combination with rituximab in patients with non-Hodgkins Lymphoma. Half of the 22 people enrolled had a positive response to the therapy, and about one-third went into complete remission from their cancer.
Dr. Advani is the PI for the study (sponsor: Forty Seven Inc) and is the lead author for the publication in the New England Journal of Medicine.
Kudos to Dr. Advani and her team in the Lymphoma group for your hard work on this clinical trial!
Mogamulizumab (sponsor: Kyowa-Kirin) was approved this week for use in Cutaneous T-Cell Lymphoma (CTCL) for patients who received 1 prior line of therapy. Stanford’s multi-disciplinary Cutaneous Lymphoma team (PI: Dr. Youn Kim) as the lead site for this study had a successful FDA inspection in December 2017, paving the way for its accelerated approval.
Hats off to the hard work of all the members of this team.
Drs. Sumit Shah and Shivaani Kummar recently participated in cancer immunotherapy educational videos for the Stanford Health Library. Their presentations are available to view below.
Understanding Cancer Immunotherapy
Dr. Sumit Shah provides an introduction to immune system related approaches to treat cancer.
Developing Effective Immune Therapies to Treat Cancer
Dr. Shivaani Kummar discusses the cancer clinical trial phases, types of immunotherapies, and developing effective novel approaches to treat cancer.
Lessons Learned: Urologic cancer immunotherapies and what is next in clinical research
Dr. Sumit Shah shares his lessons learned from clinical trials conducted to treat urologic cancers with immunotherapy.
Other Future of Cancer Care Talk Series videos available at healthlibrary.stanford.edu/videolibrary/sci.html